Napo Pharmaceuticals
Crofelemer
A proprietary gastro-intestinal compound in clinical development for four distinct product indications
R&D pipeline
Gastro Intestinal Indications
Napo intends to use the CFTR inhibitor program to build upon its significant experience in the gastrointestinal and secretory diarrhea fields with crofelemer to develop potential second generation antisecretory diarrhea products as well as to study applications in IBS related to diarrhea and/or pain, and for other GI indications.